Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue The Lancet Regional Health - Europe Année : 2024

Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

1 UMCG - University Medical Center Groningen [Groningen]
2 University of Groningen [Groningen]
3 CESP - Centre de recherche en épidémiologie et santé des populations
4 GU - Göteborgs Universitet = University of Gothenburg
5 Medical University of Graz
6 University Clinics Tuebingen [Germany]
7 Centro Hospitalar Universitário de São João [Porto]
8 Thomayer University Hospital
9 UK - Univerzita Karlova [Praha, Česká republika] = Charles University [Prague, Czech Republic]
10 Karl Landsteiner University of Health Sciences - Karl Landsteiner Privatuniversität für Gesundheitswissenschaften [Krems an der Donau, Austria]
11 OncoAge - FHU OncoAge - Pathologies liées à l’âge [CHU Nice]
12 CHU Nice - Centre Hospitalier Universitaire de Nice
13 UZA - Antwerp University Hospital [Edegem]
14 UA - University of Antwerp
15 Umeå University, Sweden
16 University Clinic Golnik
17 Hospital Universitario 12 de Octubre [Madrid]
18 UCM - Universidad Complutense de Madrid = Complutense University of Madrid [Madrid]
19 NHS Foundation Trust [London]
20 King‘s College London
21 IPATIMUP - Instituto de Patologia e Imunologia Molecular da Universidade do Porto
22 Institute for Research and Innovation in Health (i3S)
23 Faculty of Medicine University of Porto
24 University Clinic of Respiratory and Allergic Diseases Golnik
25 CNIO - Spanish National Cancer Research Center
26 The Royal Marsden NHS Foundation Trust [London]
27 Medicine Charles University and General Faculty Hospital in Prague
28 UHB-NHS Foundation - University Hospitals Birmingham NHS Foundation Trust [Birmingham, UK]
29 University Hospital of Cologne [Cologne]
Luka Brcic

Résumé

In the past two decades, the treatment of metastatic non-small cell lung cancer (NSCLC), has undergone significant changes due to the introduction of targeted therapies and immunotherapy. These advancements have led to the need for predictive molecular tests to identify patients eligible for targeted therapy. This review provides an overview of the development and current application of targeted therapies and predictive biomarker testing in European patients with advanced stage NSCLC. Using data from eleven European countries, we conclude that recommendations for predictive testing are incorporated in national guidelines across Europe, although there are differences in their comprehensiveness. Moreover, the availability of recently EMA-approved targeted therapies varies between European countries. Unfortunately, routine assessment of national/regional molecular testing rates is limited. As a result, it remains uncertain which proportion of patients with metastatic NSCLC in Europe receive adequate predictive biomarker testing. Lastly, Molecular Tumor Boards (MTBs) for discussion of molecular test results are widely implemented, but national guidelines for their composition and functioning are lacking. The establishment of MTB guidelines can provide a framework for interpreting rare or complex mutations, facilitating appropriate treatment decision-making, and ensuring quality control.
Fichier principal
Vignette du fichier
1-s2.0-S2666776224000048-main.pdf (3.28 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence

Dates et versions

hal-04626827 , version 1 (01-07-2024)

Licence

Identifiants

Citer

Vincent D. de Jager, Wim Timens, Arnaud Bayle, Johan Botling, Luka Brcic, et al.. Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries. The Lancet Regional Health - Europe, 2024, 38, pp.100838. ⟨10.1016/j.lanepe.2024.100838⟩. ⟨hal-04626827⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More